DRL up 1% on launching of Ropinirole Hydrochloride XR in US

Drug maker Dr Reddy's Laboratories gained over 1% to touch an intraday high of 1,634 on Thursday after company launched Ropinirole Hydrochloride XR tablets in the US.

June 07, 2012 / 11:27 IST

Drug maker Dr Reddy's Laboratories (DRL) gained over 1% to touch an intraday high of 1,634 on Thursday after company launched Ropinirole Hydrochloride XR tablets in the US.

Ropinirole Hydrochloride is a bioequivalent generic version of REQUIP XL that had US sales of approximately USD 58 million for the year ended March 31, 2012, according to IMS Health.

At 11:18 hours IST, the share was trading at Rs 1,616.65, up 0.12% with volumes of 21,088 shares. Market capitalisation of the company currently stands at Rs 27,441.15 crore.

first published: Jun 7, 2012 11:25 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Email address

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347